Ordering
Available Variants25 mg
CHA.85266-25mg
Price
€180.88
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.85266-25mg | €180.88 |
≥98% (HPLC), Lyn kinase activator, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C11H10N2O2 |
|---|---|
| CAS Number | 41964-07-2 |
| Molecular Weight | 202.21 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329825372 |
| NACRES | NA.77 |
| MDL number | MFCD00866900 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H319 |
| pcodes | P264 - P280 - P305 + P351 + P338 - P337 + P313 |
| Hazard Classifications | Eye Irrit. 2 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
MLR-1023, also known by its CAS number 41964-07-2, is a synthetic compound with potential therapeutic applications. Research has focused on its role as a selective inhibitor of the enzyme LRRK2, or leucine-rich repeat kinase 2, which has been implicated in the pathogenesis of Parkinsons disease. By inhibiting LRRK2, MLR-1023 may help to mitigate the neurodegenerative effects associated with this enzymes aberrant activity. Studies have demonstrated the compounds ability to cross the blood-brain barrier, suggesting its potential as a treatment for neurodegenerative disorders. Further investigation is necessary to fully elucidate the pharmacological properties and therapeutic potential of MLR-1023, but initial findings suggest that it may represent a promising lead in the development of novel treatments for Parkinsons disease and other related conditions. Ongoing research aims to explore its efficacy and safety in preclinical models.
